[PDF][PDF] Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution …
…, HA Macapinlac, MA Burgess, SR Patel… - Journal of clinical …, 2007 - imaging.cancer.gov
Purpose Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating
gastrointestinal stromal tumors (GISTs) treated with imatinib. This study evaluates whether …
gastrointestinal stromal tumors (GISTs) treated with imatinib. This study evaluates whether …
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
…, CD Blanke, M von Mehren, MF Brennan, S Patel… - The lancet, 2009 - thelancet.com
Background Gastrointestinal stromal tumour is the most common sarcoma of the intestinal
tract. Imatinib mesylate is a small molecule that inhibits activation of the KIT and platelet-…
tract. Imatinib mesylate is a small molecule that inhibits activation of the KIT and platelet-…
Prognostic factors for patients with localized soft‐tissue sarcoma treated with conservation surgery and radiation therapy: An analysis of 1225 patients
…, PWT Pisters, RE Pollock, SR Patel… - … Journal of the …, 2003 - Wiley Online Library
BACKGROUND Prognostic factors for patients with soft‐tissue sarcoma who are treated
with conservative surgery and radiation are documented poorly. METHODS The …
with conservative surgery and radiation are documented poorly. METHODS The …
A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group
…, MW Groff, NJ Liebsch, E Mendel, SH Okuno, S Patel… - Spine, 2010 - journals.lww.com
Study Design. Systematic review and modified Delphi technique. Objective. To use an
evidence-based medicine process using the best available literature and expert opinion …
evidence-based medicine process using the best available literature and expert opinion …
[PDF][PDF] Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma …
RG Maki, JK Wathen, SR Patel, DA Priebat… - J clin …, 2007 - researchgate.net
Purpose Gemcitabine as a single agent and the combination of gemcitabine and docetaxel
have activity in patients with metastatic soft tissue sarcoma. To determine if the addition of …
have activity in patients with metastatic soft tissue sarcoma. To determine if the addition of …
[HTML][HTML] Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase …
…, TV Parekh, RG Maki, SR Patel - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
… Shreyaskumar R. Patel … Maki RG, Wathen JK, Patel SR, et al. Randomized phase II
study of gemcitabine and docetaxel compared with gemcitabine alone in patients with …
study of gemcitabine and docetaxel compared with gemcitabine alone in patients with …
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Background Patients with advanced sarcomas have a poor prognosis and few treatment
options that improve overall survival. Chemotherapy and targeted therapies offer short-lived …
options that improve overall survival. Chemotherapy and targeted therapies offer short-lived …
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
…, B Chmielowski, A Le Cesne, GD Demetri, SR Patel - The Lancet, 2016 - thelancet.com
Background A non-randomised, phase 2 study showed activity and tolerability of eribulin in
advanced or metastatic soft-tissue sarcoma. In this phase 3 study, we aimed to compare …
advanced or metastatic soft-tissue sarcoma. In this phase 3 study, we aimed to compare …
We should desist using RECIST, at least in GIST
…, HA Macapinlac, MA Burgess, SR Patel… - Journal of Clinical …, 2007 - ascopubs.org
Purpose Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating
imatinib-treated gastrointestinal stromal tumors (GISTs). Response by Choi criteria, a 10% …
imatinib-treated gastrointestinal stromal tumors (GISTs). Response by Choi criteria, a 10% …
Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group
…, NJ Liebsch, E Mendel, SH Okuno, S Patel… - Journal of clinical …, 2011 - ascopubs.org
Purpose Standardized indications for treatment of tumor-related spinal instability are hampered
by the lack of a valid and reliable classification system. The objective of this study was to …
by the lack of a valid and reliable classification system. The objective of this study was to …
